Oct 18, 2023
- Pharmaceuticals
- R&D
Roche Announces Updates on Alecensa for Adjuvant Therapy in ALK-Positive Early-Stage Non-Small Cell Lung Cancer
TOKYO, October 18, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding results of a phase III clinical trial (ALINA study) for anti-cancer agent/ALK inhibitor Alecensa® (alectinib) for adjuvant therapy in ALK-positive early-stage non-small cell lung cancer.
Please refer to the link below for details of the press release:
Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
https://www.roche.com/media/releases/med-cor-2023-10-18
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
